Literature DB >> 24231500

Fathoming uric acid nephropathy.

Dilip Gude1, Sashidhar Chennamsetty, Ratan Jha.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24231500     DOI： 10.4103/1319-2442.121307

Source DB:  PubMed          Journal:  Saudi J Kidney Dis Transpl        ISSN： 1319-2442


× No keyword cloud information.
  4 in total

1.  EGF Receptor Inhibition Alleviates Hyperuricemic Nephropathy.

Authors:  Na Liu; Li Wang; Tao Yang; Chongxiang Xiong; Liuqing Xu; Yingfeng Shi; Wenfang Bao; Y Eugene Chin; Shi-Bin Cheng; Haidong Yan; Andong Qiu; Shougang Zhuang
Journal:  J Am Soc Nephrol       Date:  2015-03-18       Impact factor: 10.121

2.  Pharmacologic targeting ERK1/2 attenuates the development and progression of hyperuricemic nephropathy in rats.

Authors:  Na Liu; Liuqing Xu; Yingfeng Shi; Lu Fang; Hongwei Gu; Hongrui Wang; Xiaoqiang Ding; Shougang Zhuang
Journal:  Oncotarget       Date:  2017-05-16

3.  Crucial role of serum response factor in renal tubular epithelial cell epithelial-mesenchymal transition in hyperuricemic nephropathy.

Authors:  Long Zhao; Chenyu Li; Bin Zhou; Congjuan Luo; Yanfei Wang; Lin Che; Jun Zhao; Yan Xu
Journal:  Aging (Albany NY)       Date:  2019-11-27       Impact factor: 5.682

4.  Febuxostat attenuates ER stress mediated kidney injury in a rat model of hyperuricemic nephropathy.

Authors:  Li He; Ying Fan; Wenzhen Xiao; Teng Chen; Jiejun Wen; Yang Dong; Yiyun Wang; Shiqi Li; Rui Xue; Liyang Zheng; John Cijiang He; Niansong Wang
Journal:  Oncotarget       Date:  2017-11-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.